AIMT Aimmune Therapeutics Inc.

18.99
-0.01  -0%
Previous Close 19
Open 19
Price To Book 4.63
Market Cap 1,186,731,341
Shares 62,492,435
Volume 628,630
Short Ratio
Av. Daily Volume 527,198

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met primary endpoint - March 25, 2019.
AR101 ARTEMIS
Peanut Allergy
Phase 3 data released November 8, 2018 noted no serious adverse events
AR101 RAMSES
Peanut Allergy
PDUFA date late-January 2020. Advisory Committee meeting September 13, 2019.
AR101
Peanut Allergy
Phase 2 trial to be initiated mid-2019.
AR 201
Egg Allergy
Phase 2 trial to be initiated 2H 2019.
AR 301
Walnut Allergy
Phase 2 trial initiation announced October 15, 2018.
AR101 with adjunctive dupilumab
Peanut Allergy
Phase 3 initiation announced December 19, 2018.
AR101 POSEIDON
Peanut Allergy

Latest News

  1. Aimmune Down on Negative ICER Review on Allergy Candidate
  2. The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study
  3. Here's Why Aimmune Therapeutics Fell 7% Today
  4. Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final Report on AR101 for Peanut Allergy
  5. Edited Transcript of AIMT earnings conference call or presentation 8-May-19 8:30pm GMT
  6. Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy
  7. Here’s What Hedge Funds Think About Aimmune Therapeutics Inc (AIMT)
  8. Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Is Expected To Breakeven
  9. What Makes Aimmune Therapeutics (AIMT) a New Buy Stock
  10. Aimmune to Present at the JMP Securities Life Sciences Conference
  11. Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference
  12. Data from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut Allergy
  13. New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year
  14. Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy
  15. Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress
  16. New Study Shows More Than Half of Teens with Peanut Allergy Visited the E.R., More Than One-Third Required Hospitalization Due to Accidental Exposure to Peanut
  17. Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
  18. Aimmune to Present at RBC Capital Markets Global Healthcare Conference
  19. Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy
  20. Aimmune Therapeutics, Inc. (AIMT) Q1 2019 Earnings Call Transcript